A recent study by Zaucha et al. [1] included 106 patients with early-stage Hodgkin lymphoma. These patients were treated with 2–4 cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) or with six cycles of ABVD. These patients underwent interim FDG-PET scans after one cycle of ABVD in all 106 cases, whereas 57 (53.8%) underwent FDG-PET imaging both after one and two cycles of ABVD. After one cycle of ABVD, FDG-PET scans of 87/106 (82%) patients were scored negative (i.e. Deauville score 1–3), whereas 19/106 (18%) were scored positive (i.e. Deauville score 4–5), of whom four were excluded from further analysis because of progression and treatment escalation. Of the patients with negative interim FDG-PET results, 4/87 had an event (one progression, three relapses), whereas in the group of patients with positive interim FDG-PET results, 5/15 experienced an event (three progressions, two relapses), resulting in a negative predictive value (NPV) and positive predictive value (PPV) of 95% and 33%, respective. Of the 56 patients with FDG-PET scans performed after two cycles of ABVD, 50 (89.3%) had negative and 6 (10.7%) had positive results. Three of these latter six patients were excluded because of progression and treatment escalation. Consequently, only three patients with positive results at interim FDG-PET after two cycles were evaluable. Each of these three patients (100%) experienced an event (one progression, two relapses), whereas only 2/50 patients with negative interim FDG-PET results (4%) experienced an event (two progressions). Zaucha et al. [1] concluded FDG-PET after two cycles of ABVD to be the optimal tool that can distinguish very well between responders and non-responders.

中文翻译：

---

中期 FDG-PET 在早期霍奇金淋巴瘤中的预测价值尚未确定。

Zaucha 等人最近的一项研究。[1] 包括 106 名早期霍奇金淋巴瘤患者。这些患者接受了 2-4 个周期的阿霉素、博来霉素、长春碱和达卡巴嗪 (ABVD) 治疗，随后接受了放射治疗 (RT) 或 6 个周期的 ABVD。这些患者在所有 106 例 ABVD 一个周期后接受了中期 FDG-PET 扫描，而 57 名（53.8%）在 ABVD 一个周期和两个周期后都接受了 FDG-PET 成像。一个周期的 ABVD 后，87/106 (82%) 名患者的 FDG-PET 扫描评分为阴性（即多维尔评分 1-3），而 19/106 (18%) 名患者评分为阳性（即多维尔评分 4-5） ，其中四人因进展和治疗升级而被排除在进一步分析之外。在中期 FDG-PET 结果为阴性的患者中，4/87 发生了事件（1 次进展，3 次复发），而在中期 FDG-PET 结果阳性的患者组中，5/15 经历了一次事件（3 次进展，2 次复发），导致阴性预测值 (NPV) 和阳性预测值 (PPV) 分别为 95% 和 33% ，各自。在两个周期的 ABVD 后进行 FDG-PET 扫描的 56 名患者中，50 名（89.3%）为阴性，6 名（10.7%）为阳性。由于进展和治疗升级，后六名患者中有三名被排除在外。因此，只有 3 名患者在两个周期后的中期 FDG-PET 中有阳性结果可评估。这三名患者（100%）中的每一个都经历了一次事件（一次进展，两次复发），而只有 2/50 的中期 FDG-PET 结果为阴性的患者（4%）经历了一次事件（两次进展）。扎查等人。